Hydroxychloroquine for Primary Progressive Multiple Sclerosis-Reference-Cited by-同舟云学术

Hydroxychloroquine for Primary Progressive Multiple Sclerosis

Published:2021-10-15 Issue:6 Volume:90 Page:940-948
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol

Author:

Koch Marcus W.¹²^ORCID,Kaur Sharanjit¹,Sage Kayla¹,Kim Janet¹,Levesque‐Roy Myriam³,Cerchiaro Graziela¹,Yong Voon Wee¹^ORCID,Cutter Gary R.⁴,Metz Luanne M.¹

Affiliation:

1. Department of Clinical Neurosciences University of Calgary Calgary Canada

2. Department of Community Health Sciences University of Calgary Calgary Canada

3. Department of Neurology and Neurosurgery McGill University Montreal Canada

4. Department of Biostatistics University of Alabama at Birmingham Birmingham AL

Funder

Hotchkiss Brain Institute, University of Calgary

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.26239

Reference40 articles.

1. Primary-progressive multiple sclerosis

2. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

3. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

4. The relation between inflammation and neurodegeneration in multiple sclerosis brains

5. Cortical demyelination and diffuse white matter injury in multiple sclerosis

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selecting informative patients for phase 2 progressive trials in MS: Design considerations for phase 2 clinical trials in progressive MS;Multiple Sclerosis Journal;2024-09-08

2. Revisiting the potential of regulated cell death in glioma treatment: a focus on autophagy-dependent cell death, anoikis, ferroptosis, cuproptosis, pyroptosis, immunogenic cell death, and the crosstalk between them;Frontiers in Oncology;2024-08-09

3. Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?;Journal of Neuroimmunology;2024-08

4. Angiogenesis biomarkers discriminate multiple sclerosis phenotypes;2024-05-13

5. From progression to progress: The future of multiple sclerosis;Journal of Central Nervous System Disease;2024-05-06